Keisuke Ejima News Today

Credit Justin Hicks / IPB News Clinical trials for antiviral drugs to treat COVID-19 have produced inconsistent results. New research led by Indiana University says the problem may come down to how these trials are designed.  Indiana University assistant research scientist Keisuke Ejima and researchers at Nagoya University in Aichi, Japan, created simulations based on clinical data to analyze how COVID-19 drug trials are designed.  To best decrease the viral load, or the amount of virus in a ...

New Study Highlights Underlying Flaws In COVID-19 Antiviral Drug Clinical Trials Unable to load the audio player. playpausemuteunmute Article origination IPBS-RJC To best decrease the viral load, or the amount of virus in a person, the study found participants needed antiviral medication within two days of developing symptoms. Justin Hicks/IPB News Clinical trials for antiviral drugs to treat COVID-19 have produced inconsistent results. New research led by Indiana University says the problem m...

Study reveals contributing factor to inconsistent results in clinical trials for COVID-19 drugs Jul 8 2021 A new study suggests that significant variation in the amount of virus from person to person may be a contributing factor to inconsistent findings reported in clinical trials for antiviral COVID-19 drugs. The study is led by Keisuke Ejima, an assistant research scientist at the Indiana University School of Public Health-Bloomington. A new study suggests that significant variation in the am...

 E-Mail Every year, nearly 2.5 million U.S. high school athletes participate in contact sports. Each of these athletes sustains an average of 650 subconcussive head impacts in a single season, hits that can negatively affect brain health. A $2.9 million grant from the National Institutes of Health will help researchers at Indiana University determine whether, and to what extent, repetitive subconcussive head impacts -- impacts that do not trigger clinically detectable signs and symptoms of con...